InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,867.60
(
-0.80%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.32
(
0.11%
)
Bitcoin
64,278.34
(
0.00%
)
Post# of 251590
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119469
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 226663

Monday, 02/24/2020 6:34:51 PM

Monday, February 24, 2020 6:34:51 PM

Post# of 251590
RVNC 4Q19 results—2/14/20* cash=$533M:

https://investors.revance.com/news-releases/news-release-details/revance-reports-fourth-quarter-and-full-year-2019-financial

The $533M figure includes ~$250M net proceeds from the recent convertible-debt offering, net of the $28.9M cost of the capped-call-option hedge (https://www.sec.gov/ix?doc=/Archives/edgar/data/1479290/000119312520038556/d889444d8k.htm ).

2020 operating expenses are expected to be $220-230M (of which $95-100M is for R&D). There is no specific guidance for 2020 product revenue from either Teoxane fillers or Daxi, but any product revenue in 2020 would offset the $220-230M of operating expenses and reduce cash burn accordingly. Also, any milestone payments received from MYL for the Botox-biosimilar program would offset cash burn.

*Closing date for convertible-debt offering.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up